Windlas Biotech Limited (BOM:543329)

Market Cap	18.62B -13.3%
Revenue (ttm)	8.68B +19.2%
Net Income	667.47M +8.2%
EPS	31.44 +7.4%
Shares Out	n/a
PE Ratio	27.90
Forward PE	n/a
Dividend	5.80 (0.71%)
Ex-Dividend Date	Jul 21, 2025

Volume	1,868
Average Volume	3,214
Open	876.80
Previous Close	876.75
Day's Range	872.35 - 885.20
52-Week Range	699.35 - 1,116.40
Beta	n/a
RSI	73.08
Earnings Date	May 21, 2026

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 1,346
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543329

Financial Performance

In fiscal year 2025, Windlas Biotech's revenue was 7.60 billion, an increase of 20.43% compared to the previous year's 6.31 billion. Earnings were 609.94 million, an increase of 4.82%.